Search the Newsreel

Xchanging Solutions Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for AngioDynamics (ANGO). Shares have added about 8.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings …

Xchanging Solutions consolidated net profit rises 9.80% in the June 2026 quarter

Xchanging Solutions profit rose 10% year on year, but margins slipped from a strong March quarter

Angi Among the First Home Services Marketplaces Available in Gemini as a Connected App

Angi, a leading digital home services marketplace, announced its availability as one of the first home services marketplaces in Gemini as a connected app, further expanding its AI ecosystem. This integration allows homeowners to seamlessly transition from AI-powered questions to connecting with local professionals …

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

Key Points Interested in AngioDynamics, Inc.? Here are five stocks we like better. MedTech is expected to become AngioDynamics' majority revenue source in fiscal 2027, rising from 47% of fiscal 2026 revenue. Management forecasts 12%–15% MedTech growth, driven by Auryon, mechanical thrombectomy products and …

AngioDynamics at Canaccord Genuity conference: growth pivot deepens

AngioDynamics discussed its strategic pivot from a legacy catheter business to a high-growth MedTech portfolio at the Canaccord Genuity conference. The company highlighted 18% MedTech revenue growth in fiscal 2026, now comprising 47% of total revenue, and projected 12-15% MedTech growth for fiscal 2027. …

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

AngioDynamics, Inc. (ANGO) presented a slideshow at Canaccord Genuity's 46th Annual Growth Conference. The article, authored by SA Transcripts, highlights the company's participation in this event. SA Transcripts is responsible for publishing thousands of quarterly earnings call transcripts and other transcript-related projects on Seeking …

AngioDynamics Port Catheter Lawsuit

Wisner Baum is actively investigating claims against AngioDynamics and Navilyst Medical concerning implantable port catheters due to reported complications like infection, thrombosis, device fracture, and migration. The AngioDynamics Port Catheter MDL, centralized in California, has grown to over 400 pending actions as of July …

Three Days Left To Buy Xchanging Solutions Limited (NSE:XCHANGING) Before The Ex-Dividend Date

Angi (ANGI) Stock Fair Value Moves Lower As Analysts Weigh Execution Risks

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Angi's latest analyst update centers on a reset in price targets, with fair value …

(ANGO) Price Dynamics and Execution-Aware Positioning

This article from Stock Traders Daily provides an AI-driven analysis of Angiodynamics Inc. (NASDAQ: ANGO), highlighting strong sentiment across all horizons and significant upside potential due to a lack of resistance levels. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk …

AngioDynamics, Inc. (ANGO) stock price, news, quote and history

This article provides comprehensive financial information for AngioDynamics, Inc. (ANGO), including its current stock price, trading activity, key financial metrics, and an overview of its medical technology products. It also features performance comparisons against the S&P 500, earnings trends, analyst ratings, and a list …

Sanginita Chemicals Wins Shareholder Nod for Board Revamp and Rebrand to Agastya Energy and Infrastructure

Sanginita Chemicals Wins Shareholder Nod for Board Revamp, Name Change and Shift to Haryana

Sanginita Chemicals Wins Shareholder Nod for Board Revamp and Strategic Rebranding

Truist Financial Keeps Their Buy Rating on Angi (ANGI)

Truist Financial

AngioDynamics SmartPort Infection Lawsuit Alleges Defective Port Caused Sepsis

A Pennsylvania man has filed a lawsuit against AngioDynamics and Navilyst Medical, alleging that a defective SmartPort catheter caused a severe infection and sepsis, necessitating its surgical removal. The complaint claims that defects in the port catheter promoted bacterial growth and that the companies …

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

AngioDynamics (ANGO) faces a trade-off between its rapidly expanding Med Tech platforms and persistent margin pressure from tariffs and rising operating costs. While NanoKnife, Auryon, and AlphaVac show strong growth potential and strategic importance, the company's valuation is mixed, and a Zacks Rank #4 …

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

AngioDynamics, Inc. ANGO has set an initial fiscal 2027 framework that keeps its Med Tech transformation at the center of the investment case. Faster growth from its priority platforms is expected to lift sales, but margin pressure and continued losses remain material constraints. The …

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

AngioDynamics (ANGO) shares have significantly outperformed the market, gaining 33.5% in three months, driven by its shift towards higher-margin Med Tech platforms like NanoKnife and Auryon. While Med Tech growth and product differentiation support the company's momentum, concerns about valuation, tariff impact on earnings …

Zacks Research Reduces Earnings Estimates for AngioDynamics

Angi Inc. (ANGI) CEO receives 200,000 RSUs vesting over four years

Angi Inc.'s CEO, Kip Jeffrey W, was granted 200,000 Restricted Stock Units (RSUs) on August 3, 2026. These RSUs, each representing a share of Class A Common Stock, will vest in four equal annual installments, subject to his continued employment. Following this grant, Mr. …

Angi Inc. (ANGI) awards 100,000 RSUs to growth chief executive

Angi Inc. (ANGI) has granted 100,000 Restricted Stock Units (RSUs) to its Chief Growth Officer, Glenn Orchard. These RSUs represent a contingent right to receive Class A Common Stock and will vest in four equal annual installments starting August 3, 2026, subject to his …

Angi Inc. (ANGI) grants director 40,257 RSUs vesting over three years

Angi Inc. director Michael F. Steib was granted 40,257 Restricted Stock Units (RSUs) on August 4, 2026. These RSUs represent a contingent right to receive one share of Class A Common Stock each. The units will vest in three equal annual installments, beginning on …

Angi Inc (ANGI) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Angi Inc (ANGI), detailing its current earnings forecast score and an average price target of $17.50 from 7 analysts. It includes a peer comparison and addresses frequently asked questions regarding expected revenue, price targets, and past EPS …

Q3 EPS Estimates for AngioDynamics Reduced by Zacks Research

AngioDynamics, Inc. $ANGO Shares Purchased by Lazard Asset Management LLC

Lazard Asset Management LLC significantly increased its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 1,328.2% during the first quarter, now owning 154,578 shares valued at $1.76 million. This comes as AngioDynamics exceeded Q1 earnings expectations, reporting an adjusted loss of $0.07 per share on $86.61 …

Angi Q2 Earnings Call Highlights

Key Points Interested in Angi Inc.? Here are five stocks we like better. Second-quarter performance weakened: Revenue declined 11% year over year, including a 34% drop in network revenue, as Angi reduced lower-quality marketing and homeowner demand shifted toward smaller projects. The company expects …

Angi (ANGI) Stock Sinks As Margin Erosion Undercuts Turnaround Hopes

Goodwill hit and 11% revenue drop pressure Angi (NASDAQ: ANGI)

Angi Inc. Earnings Release and Letter to Shareholders Available on Company’s Website

Angi Inc. has released its second-quarter financial results and a letter to shareholders from CEO Jeff Kip, which are accessible on the investor relations section of its website. The company will also host a conference call on August 5, 2026, at 8:30 a.m. ET …

Senior Vice President of Regulatory Affairs Warren Nighan Sold A Bunch Of Shares In AngioDynamics

Warren Nighan, Senior Vice President of Regulatory Affairs at AngioDynamics, recently sold US$344k worth of stock, representing 27% of his holding. While insiders did buy some shares in the last year, the overall trend points to more selling than buying. This sale, the largest …